Targovax to present at forthcoming conference

Oslo, 16 November 2016: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present a corporate overview at the following conference:

Biotech and Money Inv€$tival Showcase in partnership with Jefferies
Date: 18 November 2016
Participants: Øystein Soug (CEO) and Magnus Jäderberg (CMO)
Presentation time: 12:00 GMT
Venue: The Waldorf Hilton Hotel, London, UK

The presentation will be available to download at www.targovax.com following this event.

Targovax will release its third quarter 2016 financial results on 17 November 2016. The report can also be found on our website.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Jan Petter Stiff - Crux Advisers (Norway)
Phone: +47 995 13 891
Email: stiff@crux.no

Julia Phillips/Simon Conway - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com

About Targovax
Arming the patient's immune system to fight cancer

Targovax (OSE: TRVX) is a clinical stage company focused on developing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. The Company's pipeline is created from two novel proprietary platforms, with three therapeutic candidates in clinical development covering six indications including melanoma, mesothelioma, ovarian cancer and resected pancreatic cancer. Targovax's strategy is to bring products to market directly in those indications where it already has Orphan drug status and to partner with pharmaceutical companies in larger disease areas with significant commercial potential.